Pfizer Inc PFE

$29.31 -0.49 (-1.64%)

Valuation

Market cap
169,793,280,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.85
Forward PE
10.20
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
11,694,272
Avg volume
32,030,959
Day's range
$29.26 – $29.82
Shares out
5,699,674,000
Stochastic %K
46%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

A_Train1 Oct 28, 4:02 PM
$PFE $30…then selloff…makes sense, maybe? 🤷‍♂️
0 replies
ddirk Oct 28, 3:47 PM
$NVAX $PFE Jj and novax need to wake up, all they have been saying (not much) is smoke/mirrors.
0 replies
zustrelaax Oct 28, 3:42 PM
$PFE $NVAX enough of waiting
0 replies
MrPeanutEsquire Oct 28, 2:49 PM
$PFE Another pfizer for lilly this month. I wish we could have one...
0 replies
PFElinepfrenzy1990 Oct 28, 11:56 AM
$PFE - Pathetic for breakfast again 👩🏻‍🍳
0 replies
Parlandoconme Oct 28, 10:42 AM
$TOMZ poor ray. its groundhog day again. you are still stuck with shares you bought way to high from me in 2019. Oh well, why dont you sell low and write it off? lol. Steramist is crushing sales in biopharma and food safety. easily hitting the $12M mark in 2026. $MCD spray your burgers $PEP Spray the mist on those damn manufacturing machines. $PFE
0 replies
jackofalltrade Oct 28, 10:24 AM
$PFE Citi analysts said the earlier-line label expansions in RRMM represent a $1.32 billion opportunity for the drug by 2032. Additional trials are underway to move the drug further up the line to first line.
0 replies
LoneBroker Oct 28, 4:27 AM 0 replies